Pfizer to acquire Seagen for $43 billion

By The Science Advisory Board staff writers

March 13, 2023 -- Pfizer will acquire Seagen, a firm specializing in the discovery and development of treatments for cancer, the firms announced on Monday.

Under the terms of a merger agreement, Pfizer will pay $229 per Seagen share, for a total of $43 billion. The transaction was unanimously approved by the boards of directors of both firms.

Pfizer expects to finance the transaction substantially through $31 billion of new, long-term debt, and the balance from a combination of short-term financing and existing cash. The companies expect to complete the transaction in late 2023 or early 2024.

The proposed combination will double Pfizer's early-stage oncology clinical pipeline, contributing Seagen's specialization in antibody-drug conjugate (ADC) technology to Pfizer's extensive cancer portfolio.

ADCs work across a broad range of cancers to preferentially kill cancer cells, thereby limiting off-target toxicity. Seagen's portfolio includes three ADCs -- Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), and Tivdak (tisotumab vedotin) -- as well as the drug Tukysa (tucatinib).

Seagen anticipates $2.2 billion of revenue in 2023, a year-over-year increase of approximately 12%. Taking into consideration the expected growth trajectories for these medicines along with drug candidates that could emerge from Seagen's pipeline, Pfizer believes that Seagen could contribute more than $10 billion in risk-adjusted revenues in 2030, with the potential for significant growth beyond 2030.

CytoReason and Pfizer extend collaboration
CytoReason has extended its collaboration agreement with Pfizer to investigate challenging biological questions that potentially inform the development...
Seagen, RemeGen partner on HER2-targeted ADCs
Oncology pharmaceutical developer Seagen has signed an exclusive license and co-development agreement with RemeGen for an HER2-targeted antibody-drug...
Merck invests $1B in Seagen
Merck has invested in oncology pharmaceutical developer Seagen in a deal worth $1 billion in equity investment.

Copyright © 2023

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter